News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Merck KGaA MS Pill Cladribine Rejected by European Medicines Evaluation Agency
September 24, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
FRANKFURT, Sept 24 (Reuters) - European regulators dealt Merck KGaA (MRCG.DE) a major blow by recommending against its biggest pipeline drug, multiple sclerosis (MS) pill cladribine, adding to a string of setbacks at the company's drugs unit.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Regulatory
Europe
MORE ON THIS TOPIC
Podcast
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
November 4, 2026
·
1 min read
·
Jef Akst
Psychedelics
Compass to submit psilocybin depression drug for approval imminently after stock wobbles
November 3, 2026
·
2 min read
·
Heather McKenzie
FDA
UniQure snags May Day decision date for Huntington’s gene therapy after arduous year
November 2, 2026
·
2 min read
·
Heather McKenzie
FDA
Plug-and-play gene therapy: FDA executes on vision that’s been in the works for years
November 2, 2026
·
6 min read
·
Heather McKenzie
